Validation and reproducibility assessment of tigecycline MIC determinations by etest

Journal of Clinical Microbiology

Volumn 45, Issue 8, 2007, Pages 2474-2479

  Bolmström, Anne ^a   Karlsson, Åsa ^a   Engelhardt, Anette ^a   Ho, Phion ^a   Petersen, Peter J ^b   Bradford, Patricia A ^b   Jones, C Hal ^b,c  

^a AB BIODISK   (Sweden)

^b WYETH RESEARCH   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TIGECYCLINE;

AEROBIC BACTERIUM; ANAEROBE; ANTIBIOTIC SENSITIVITY; ARTICLE; CULTURE MEDIUM; DILUTION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; REPRODUCIBILITY; STREPTOCOCCUS PNEUMONIAE; TEST STRIP;

ANTI-BACTERIAL AGENTS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; REPRODUCIBILITY OF RESULTS;

HAEMOPHILUS INFLUENZAE; NEGIBACTERIA; POSIBACTERIA; STREPTOCOCCUS PNEUMONIAE;

EID: 34548075565     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00089-07     Document Type: Article

References (19)

1. Babinchak, T., E. J. Ellis-Grosse, N. Dartois, G. M. Rose, and E. Loh. 2005. The efficacy and safety of tigecycline in the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis. 41:S354-S367.
2. Baker, C. N., S. A. Stacker, D. H. Culver, and C. Thornsberry. 1991. Comparison of the E Test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria. J. Clin. Microbiol. 29:533-538.
3. Bradford, P. A., P. J. Petersen, M. Young, C. H. Jones, M. Tischler, and J. O'Connell. 2005. Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method. Antimicrob. Agents Chemother. 49:3903-3909.
4. Bradford, P. A., D. T. Weaver-Sands, and P. J. Petersen. 2005. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials for complicated skin and skin structure infections and complicated intra-abdominal infections. Clin. Infect. Dis. 41(Suppl. 5):S315-S332.
5. Brown, D. F., and L. Brown. 1991. Evaluation of the E test, a novel method of quantifying antimicrobial activity. J. Antimicrob. Chemother. 27:185-190.
6. Citron, D. M., M. I. Ostovari, A. Karlsson, and E. J. Goldstein. 1991. Evaluation of the E test for susceptibility testing of anaerobic bacteria. J. Clin. Microbiol. 29:2197-2203.
7. CLSI. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 7th ed. Approved standard M7-A7. CLSI, Wayne, PA.
8. CLSI. 2006. Performance standards for antimicrobial susceptibility testing: M100-S16, 16th informational supplement. CLSI, Wayne, PA.
9. Ellis-Grosse, E., T. Babinchak, N. Dartois, G. Rose, and E. Loh. 2005. The efficacy and safety of tigecycline in the treatment of skin and skin structure infections: results of two double-blind phase 3 comparison studies with vancomycin/aztreonam. Clin. Infect. Dis. 41:S341-S353.
10. Food and Drug Administration. 2003. Class II special controls guidance document: antimicrobial susceptibility test systems (AST) - guidance for industry. U.S. Food and Drug Administration, Washington, DC. [Online.] http://www.fda.gov/cdrh/oivd/guidance/631.pdf.
11. Hirata, T., A. Saito, K. Nishino, N. Tamura, and A. Yamaguchi. 2004. Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936). Antimicrob. Agents Chemother. 48:2179-2184.
12. Hoban, D., S. Bouchillon, B. Johnson, J. Johnson, and M. Dowzicky. 2005. In vitro activity of tigecycline against 6792 gram-negative and gram-positive clinical isolates from the global tigecycline evaluation and surveillance trial (TEST Program 2004). Diagn. Microbiol. Infect. Dis. 52:215-227.
13. Jones, C. H., and P. J. Petersen. 2005. Tigecycline: a review of preclinical and clinical studies of the first-in-class glycylcycline antibiotic. Drugs Today 41:637-659.
14. Jones, C. H., M. Tuckman, A. Y. Howe, M. Orlowski, S. Mullen, K. Chan, and P. A. Bradford. 2006. Diagnostic PCR analysis of the occurrence of methicillin and tetracycline resistance genes among Staphylococcus aureus isolates from phase 3 clinical trials of tigecycline for complicated skin and skin structure infections. Antimicrob. Agents Chemother. 50:505-510.
15. NCCLS. 2001. Development of in vitro susceptibility testing criteria and quality control parameters. Approved guideline M23-A2, 2nd ed., vol. 18. National Committee for Clinical Laboratory Standards, Villanova, PA.
16. NCCLS. 2004. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard M11-A6, 6th ed., vol. 24. National Committee for Clinical Laboratory Standards, Wayne, PA.
17. Petersen, P. J., and P. A. Bradford. 2005. Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates. Antimicrob. Agents Chemother. 49:3910-3918.
18. Petersen, P. J., N. V. Jacobus, W. J. Weiss, P. E. Sum, and R. T. Testa. 1999. In vitro and in vivo antimicrobial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 43:738-744.
19. Roberts, M. C. 2003. Tetracycline therapy: update. Clin. Infect. Dis. 36:462-467.